Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 214.86% from the company’s previous close.

Several other brokerages have also recently issued reports on ZVRA. Guggenheim set a $21.00 price target on shares of Zevra Therapeutics and gave the company a “buy” rating in a research report on Tuesday, February 4th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $22.14.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA opened at $7.94 on Wednesday. The company’s 50 day moving average price is $7.93 and its two-hundred day moving average price is $8.14. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The firm has a market cap of $423.81 million, a PE ratio of -4.03 and a beta of 1.98. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. Equities research analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Insider Transactions at Zevra Therapeutics

In other news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This trade represents a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the completion of the transaction, the executive vice president now owns 29,486 shares of the company’s stock, valued at $231,759.96. The trade was a 26.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock worth $674,176 over the last quarter. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently bought and sold shares of ZVRA. BNP Paribas Financial Markets purchased a new position in Zevra Therapeutics during the fourth quarter valued at approximately $53,000. XTX Topco Ltd purchased a new position in Zevra Therapeutics during the third quarter valued at approximately $94,000. China Universal Asset Management Co. Ltd. purchased a new position in Zevra Therapeutics during the fourth quarter valued at approximately $94,000. Intech Investment Management LLC bought a new stake in Zevra Therapeutics during the third quarter valued at approximately $95,000. Finally, Virtu Financial LLC bought a new stake in Zevra Therapeutics during the third quarter valued at approximately $127,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.